Literature DB >> 22470116

Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa.

Neang S Ly1, Jenny Yang, Jurgen B Bulitta, Brian T Tsuji.   

Abstract

The in vitro pharmacodynamics of colistin against Pseudomonas aeruginosa PAO1 wild-type and isogenic knockout strains of phoP and pmrA were evaluated. Colistin killing at subinhibitory concentrations was greater against the phoP and pmrA mutants than the wild type within the first 8 h: the concentration that results in 50% of maximal effect (EC(50)) of the pmrA mutant (0.413 mg/liter) was less than that of the wild type (0.718 mg/liter) (P < 0.05). An in vitro pharmacodynamic model simulating human colistin regimens displayed initial killing followed by regrowth in the phoP mutant and gradual regrowth in the pmrA mutant and wild type.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22470116      PMCID： PMC3370801          DOI： 10.1128/AAC.06380-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa.

Authors:  L Zhang; P Dhillon; H Yan; S Farmer; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Role of divalent cations in the action of polymyxin B and EDTA on Pseudomonas aeruginosa.

Authors:  M R Brown; J Melling
Journal:  J Gen Microbiol       Date:  1969-12

3.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

4.  An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor.

Authors:  M S Trent; A A Ribeiro; S Lin; R J Cotter; C R Raetz
Journal:  J Biol Chem       Date:  2001-09-04       Impact factor: 5.157

5.  Design of Gram-negative selective antimicrobial peptides.

Authors:  S A Muhle; J P Tam
Journal:  Biochemistry       Date:  2001-05-15       Impact factor: 3.162

6.  Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.

Authors:  Yoriko Harigaya; Jürgen B Bulitta; Alan Forrest; George Sakoulas; Alan J Lesse; Joseph M Mylotte; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

7.  Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.

Authors:  M Denton; K Kerr; L Mooney; V Keer; A Rajgopal; K Brownlee; P Arundel; S Conway
Journal:  Pediatr Pulmonol       Date:  2002-10

8.  Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.

Authors:  Joseph B McPhee; Shawn Lewenza; Robert E W Hancock
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

9.  PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A.

Authors:  Samuel M Moskowitz; Robert K Ernst; Samuel I Miller
Journal:  J Bacteriol       Date:  2004-01       Impact factor: 3.490

10.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790
View more
  11 in total

Review 1.  Roles of two-component regulatory systems in antibiotic resistance.

Authors:  Aimee Rp Tierney; Philip N Rather
Journal:  Future Microbiol       Date:  2019-05-08       Impact factor: 3.165

2.  Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Authors:  Neang S Ly; Zackery P Bulman; Jürgen B Bulitta; Christopher Baron; Gauri G Rao; Patricia N Holden; Jian Li; Mark D Sutton; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Authors:  Zackery P Bulman; Neang S Ly; Justin R Lenhard; Patricia N Holden; Jürgen B Bulitta; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Authors:  Neang S Ly; Jürgen B Bulitta; Gauri G Rao; Cornelia B Landersdorfer; Patricia N Holden; Alan Forrest; Phillip J Bergen; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2015-02-23       Impact factor: 5.790

5.  Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.

Authors:  Yu-Wei Lin; Heidi H Yu; Jinxin Zhao; Mei-Ling Han; Yan Zhu; Jesmin Akter; Hasini Wickremasinghe; Hasini Walpola; Veronika Wirth; Gauri G Rao; Alan Forrest; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 6.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

7.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

Review 8.  Targeting a highly conserved domain in bacterial histidine kinases to generate inhibitors with broad spectrum activity.

Authors:  Conrad A Fihn; Erin E Carlson
Journal:  Curr Opin Microbiol       Date:  2021-04-28       Impact factor: 7.584

9.  Role of the Vibrio cholerae matrix protein Bap1 in cross-resistance to antimicrobial peptides.

Authors:  Marylise Duperthuy; Annika E Sjöström; Dharmesh Sabharwal; Fatemeh Damghani; Bernt Eric Uhlin; Sun Nyunt Wai
Journal:  PLoS Pathog       Date:  2013-10-03       Impact factor: 6.823

10.  PmrA/PmrB Two-Component System Regulation of lipA Expression in Pseudomonas aeruginosa PAO1.

Authors:  Wu Liu; Menggang Li; Liangcheng Jiao; Pengbo Wang; Yunjun Yan
Journal:  Front Microbiol       Date:  2018-01-15       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.